SOUTH CAROLINA – April 7, 2026 – General Prognostics (GPx) develops clinically validated digital biomarkers that transform consumer wearables into continuous biomarker monitoring platforms. Its CardioID software detects early physiologic changes associated with heart failure deterioration. Operating at the intersection of digital health and cardiovascular medicine, GPx plans its first FDA submission in Q2 2026.
Solutions
General Prognostics (GPx) has developed CardioID, a software platform that turns consumer smartwatches into continuous biomarker-monitoring tools for chronic disease management. CardioID analyzes wearable-derived physiologic signals to detect early changes associated with worsening heart failure, enabling clinicians to intervene before symptoms appear or hospitalization occurs. In validation studies across 11 hospitals in the United States, Japan, and India, CardioID demonstrated strong predictive performance for heart failure deterioration (AUC 0.87) and identified worsening approximately two weeks before confirmatory blood testing. GPx is preparing its first software-as-a-medical-device submission to the U.S. FDA in Q2 2026.
Strengths
- Clinical Validation: CardioID’s digital biomarker algorithms have been validated across 11 hospitals in the United States, Japan, and India, demonstrating strong predictive performance for heart failure decompensation and enabling earlier detection of physiologic deterioration before symptoms appear.
- Non-Invasive Monitoring: GPx converts widely available consumer smartwatches into medical-grade monitoring tools, enabling continuous biomarker assessment without implants or frequent blood draws and allowing scalable monitoring for large patient populations.
- Regulatory Pathway: GPx is preparing its first software-as-a-medical-device submission to the U.S. FDA in Q2 2026, positioning the platform for near-term clinical deployment.
- Pharma Applications: Continuous digital biomarker monitoring can support pharmaceutical development by improving trial recruitment, enabling earlier detection of therapeutic response and generating longitudinal physiologic data.
Meet the Team
From left to right:
Sean Matsuoka | Co-Founder and Chief Executive Officer
Sidhant Jena | Founding Advisor